Cumberland Pharmaceuticals Inc. CPIX
- Market cap
- $120.0M
- P/E
- 0.0×
Follow CPIX
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.20 | 5.28 | 5.06 | 4.19 | 2.77 | 2.20 | 1.89 | 1.43 | 1.04 | 1.85 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 6.00 | 7.96 | 7.45 | 6.99 | 5.44 | 7.51 | 5.65 | 2.91 | 3.05 | 7.25 |
High Price
|
|||
| 82 | 84 | 80 | 94 | 90 | 83 | 85 | 91 | 91 | 93 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 33 | 41 | 29 | 34 | 37 | 36 | 42 | 40 | 38 | 45 |
Revenue
|
|||
| 81.96% | 82.09% | 79.50% | 78.42% | 76.89% | 75.51% | 78.29% | 84.66% | 82.61% | 85.02% |
Gross Margin
|
|||
| (1) | (4) | (11) | (9) | (7) | (6) | (6) | (6) | (6) | (3) |
EBT
|
|||
| (4.04%) | (9.42%) | (36.82%) | (27.02%) | (17.55%) | (15.46%) | (13.29%) | (15.89%) | (17.08%) | (6.31%) |
EBT Margin
|
|||
| (1) | (8) | (7) | (4) | (3) | (4) | (6) | (6) | (6) | (3) |
Net Income
|
|||
| 2 | 3 | 3 | 4 | 5 | 5 | 5 | 8 | 5 | 4 |
Depreciation
|
|||
| 2.03 | 2.59 | 1.88 | 2.23 | 2.47 | 2.41 | 2.88 | 2.77 | 2.69 | 3.00 |
Revenue/Sh
|
|||
| (0.06) | (0.50) | (0.45) | (0.23) | (0.22) | (0.24) | (0.38) | (0.44) | (0.46) | (0.19) |
Earnings/Sh
|
|||
| 0.04 | (0.03) | 0.20 | 0.20 | 0.36 | 0.43 | 0.58 | 0.43 | (0.04) | 0.33 |
Cash Flow/Sh
|
|||
| (0.13) | (0.09) | (0.27) | (0.07) | (0.14) | (0.02) | (0.14) | (0.03) | (0.01) | (0.01) |
Capex/Sh
|
|||
| (0.10) | (0.13) | (0.07) | 0.13 | 0.22 | 0.40 | 0.44 | 0.39 | (0.06) | 0.32 |
Free CF/Sh
|
|||
| 4.50 | 4.02 | 3.56 | 3.32 | 3.09 | 2.86 | 2.47 | 2.05 | 1.60 | 1.65 |
Book Value/Sh
|
|||
| 16 | 16 | 16 | 15 | 15 | 15 | 15 | 14 | 14 | 15 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 2.88 | 2.73 | 3.21 | 2.31 | 1.19 | 1.93 | 0.80 | 0.67 | 0.88 | 1.33 |
PS Ratio
|
|||
| 1.30 | 1.76 | 1.69 | 1.55 | 0.95 | 1.63 | 0.94 | 0.90 | 1.48 | 2.41 |
PB Ratio
|
|||
| 1.49 | 1.75 | 2.66 | 2.05 | 0.96 | 1.63 | 0.72 | 0.54 | 0.81 | 1.30 |
EV/Sales
|
|||
| (31.45) | (35.13) | (67.04) | 34.60 | 10.90 | 9.78 | 4.74 | 3.77 | (38.68) | 12.21 |
EV/FCF
|
|||
| 1 | (1) | 3 | 3 | 5 | 6 | 8 | 6 | (1) | 5 |
Op' Cash Flow
|
|||
| (2) | (1) | (4) | (1) | (2) | 0 | (2) | 0 | 0 | 0 |
Capex
|
|||
| (2) | (2) | (1) | 2 | 3 | 6 | 6 | 6 | (1) | 5 |
FCF
|
|||
| 51 | 51 | 31 | 26 | 24 | 26 | 17 | 8 | 5 | 0 |
Working Cap'
|
|||
| 4 | 10 | 20 | 19 | 16 | 16 | 16 | 13 | 15 | 5 |
Total Debt
|
|||
| (46) | (40) | (16) | (9) | (9) | (11) | (3) | (6) | (3) | (6) |
Net Debt
|
|||
| 73 | 64 | 56 | 51 | 47 | 43 | 36 | 29 | 23 | 25 |
Sh' Equity
|
|||
| (1.02%) | (8.55%) | (6.76%) | (3.26%) | (3.32%) | (3.88%) | (6.28%) | (7.19%) | (8.24%) | (3.72%) |
ROA
|
|||
| (3.31%) | (10.79%) | (17.75%) | (13.73%) | (10.46%) | (15.22%) | (10.94%) | (25.17%) | (20.24%) | (9.51%) |
ROIC
|
|||
| (1.26%) | (11.64%) | (11.65%) | (6.63%) | (6.82%) | (7.84%) | (14.18%) | (19.25%) | (25.02%) | (12.05%) |
ROE
|
|||
Cumberland Pharmaceuticals Inc. peers in Drug Manufacturers Specialty & Generic
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| PROCF Sofgen Pharma S.A | $114.0M | 0.0× | Compare |
| BGM BGM Group Ltd. | $104.6M | 4.0× | Compare |
| CTOR Citius Oncology, Inc. | $97.6M | 0.0× | Compare |
| CLVR Clever Leaves Holdings Inc. | $96.5M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| OGI Organigram Global Inc. | $155.1M | 2.4× | Compare |
| LFCR Lifecore Biomedical, Inc. | $162.4M | 0.0× | Compare |
| DERM Journey Medical Corporation | $178.4M | 0.0× | Compare |
| CRDL Cardiol Therapeutics Inc. | $202.1M | 0.0× | Compare |
Cumberland Pharmaceuticals Inc. (CPIX) key facts
- Cumberland Pharmaceuticals Inc. (CPIX) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
- Cumberland Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.5 million, up 17.6% from fiscal 2024.
- Cumberland Pharmaceuticals Inc. reported a net loss of $2.9 million, or a loss of $0.19 per share, for fiscal 2025.
- As of September 25, 2026, CPIX traded at $7.61, a market capitalization of $120.0 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 2.7× sales.
- Return on equity was −12.1% and debt-to-equity 0.00.
Cumberland Pharmaceuticals Inc. (CPIX) Latest News
5 Aug
Cumberland Pharmaceuticals Inc. outlined strategic initiatives and operational updates during its Q2 2026 earnings call, covering progress across its pharmaceutical portfolio and forward-looking plans. Strategic updates from the earnings call could moderately affect financial performance and competitive positioning without fundamentally transforming the company's outlook.
4 Aug
Cumberland Pharmaceuticals Inc. (CPIX) released Q2 earnings call highlights covering financial results, operational updates, and outlook. Q2 earnings updates typically influence short-term investor sentiment and valuation without major strategic shifts.
Cumberland Pharmaceuticals Inc. issued a company update along with its Q2 2026 financial results. Quarterly financial results and updates can moderately affect valuation and investor views.
1 Jul
Apotex completes previously announced strategic transaction with Cumberland Pharmaceuticals Inc. (CPIX). Completed strategic transaction with Apotex shifts Cumberland's operational trajectory and market positioning.
Apotex completes previously announced strategic transaction with Cumberland Pharmaceuticals. Completed strategic transaction with Apotex alters Cumberland's market positioning and operational trajectory.
Cumberland Pharmaceuticals closes strategic transaction with Apotex. Strategic transaction closure with Apotex positions Cumberland for expanded market reach and revenue growth.
26 Jun
Cumberland Pharmaceuticals presented updated FIGHT DMD trial results at the Parent Project Muscular Dystrophy Annual Conference. Updated FIGHT DMD trial results may significantly influence Cumberland Pharmaceuticals' market performance and future development plans.
2 Jun
Cumberland Pharmaceuticals and Vanderbilt Health announce potential new therapy to prevent cancer metastasis. Partnership to develop anti-metastasis therapy positions company for major growth in oncology market.
Cumberland Pharmaceuticals launches Vibativ in China to expand global reach. Vibativ launch in China opens major new market and boosts international revenue potential.
28 May
Cumberland Pharmaceuticals Inc. launches Vibativ in China. Vibativ launch in China marks major international expansion with revenue upside for Cumberland Pharmaceuticals.
6 May
Cumberland Pharmaceuticals Inc. (CPIX) reported a Q1 loss while planning a $100 million deal with Apotex. Planned $100M Apotex deal signals major strategic infusion despite Q1 loss.
Cumberland Pharmaceuticals Inc. (CPIX) released summary of Q1 2026 earnings call highlighting financial results, operations, and outlook. Q1 earnings call summary reveals financial performance and guidance with moderate influence on investor sentiment and trajectory.
5 May
Cumberland Pharmaceuticals Inc. (CPIX) integrates its commercial business with Apotex to streamline operations, expand market reach, and leverage Apotex's distribution network for better product commercialization. Integrating commercial operations with Apotex enables major strategic expansion in distribution and sales, significantly altering CPIX's market trajectory and investor outlook.
Cumberland Pharmaceuticals Inc. (CPIX) released highlights from its Q1 earnings call, covering financial results, product updates, and strategic outlook. Q1 earnings call highlights detail financial performance and operations with moderately noticeable influence on investor sentiment and trajectory.
Cumberland Pharmaceuticals Inc. (CPIX) reported Q1 2026 financial results and issued a company update. Q1 financial results disclosure affects key financial performance metrics and investor sentiment.
24 Apr
Cumberland Pharmaceuticals Inc. (CPIX) agrees to sell its drug portfolio to Apotex for $100 million. Selling the drug portfolio for $100 million delivers a major cash boost and represents a significant strategic pivot reshaping the company's future operations and market position.
23 Apr
Cumberland Pharmaceuticals (CPIX) shares surge following announcement of a $100 million transaction with Apotex. $100M Apotex transaction constitutes a major strategic move likely to significantly enhance Cumberland Pharmaceuticals' financial position and market trajectory.
Apotex announces strategic transaction with Cumberland Pharmaceuticals Inc. (CPIX) to integrate their U.S. branded pharmaceutical businesses. Strategic transaction integrates U.S. branded businesses, marking a major shift in Cumberland's operations and competitive positioning.
Apotex integrates its U.S. branded businesses with Cumberland Pharmaceuticals via strategic transaction. Business integration expands Cumberland portfolio and market position substantially.
Cumberland Pharmaceuticals Inc. (CPIX) announces strategic transaction to integrate its commercial business with Apotex, enhancing operational efficiency and market reach. Strategic integration of commercial operations with Apotex constitutes a major move reshaping CPIX's business model and growth prospects.
16 Apr
Cumberland Pharmaceuticals announces FDA approval for expanded indication of Caldolor (ibuprofen injection) for pediatric patients aged 3 months and older, and launches new brand website. Expanded pediatric indication for Caldolor broadens market access and drives potential revenue growth for key product.
10 Mar
Cumberland Pharmaceuticals Inc. (CPIX) narrowed its Q4 net loss year-over-year to $1.3 million from $3.2 million, driven by Talicia sales growth to $6.9 million from near-zero, boosting total revenue 22% to $10.2 million. Talicia launch significantly boosted Q4 sales and narrowed losses, enhancing financial performance and market outlook.
4 Mar
Cumberland Pharmaceuticals Inc. (CPIX) Q4 2025 earnings call highlights revenue surge alongside key financial and operational updates. Revenue surge in Q4 2025 indicates major positive shift in financial performance, significantly influencing market sentiment and future trajectory.
3 Mar
Cumberland Pharmaceuticals Inc. (CPIX) reported 31% revenue growth in the fourth quarter of 2025. 31% Q4 revenue growth represents significant financial improvement likely boosting investor sentiment and future performance.
Cumberland Pharmaceuticals Inc. (CPIX) released Q4 earnings call highlights covering financial performance, product updates, and future outlook. Q4 earnings highlights reveal financial results and strategic directions that moderately affect CPIX's performance and investor views.
Cumberland Pharmaceuticals Inc. (CPIX) reported Q4 results with revenue of $43.4 million, up 6% from last year, net income of $10.3 million or $0.46 per share versus $0.37, driven by higher Crystevas sales and new product launches. Q4 earnings beat expectations and showed revenue growth, moderately boosting financial performance and investor confidence.
25 Feb
Cumberland Pharmaceuticals Inc. (CPIX) and RedHill Pharmaceuticals have commenced joint commercialization of Talicia® in the United States. Joint U.S. commercialization of Talicia® launches a new key product partnership enhancing CPIX revenue potential and market position.
Cumberland Pharmaceuticals Inc. launches U.S. promotion of Talicia®, its FDA-approved therapy for Helicobacter pylori infection in adults. Launching U.S. promotion of Talicia® drives revenue growth through expanded market access for a key patented product.
4 Feb
Cumberland Pharmaceuticals Inc. has received FDA Fast Track Designation for its Ifetroban program aimed at treating Duchenne Muscular Dystrophy. This designation is intended to expedite the development and review process for drugs that address unmet medical needs, potentially allowing for quicker access to the treatment for patients. The company aims to advance its clinical trials and enhance its market position in the rare disease sector. FDA Fast Track Designation can significantly accelerate the development timeline and market entry of Ifetroban, impacting the company's future performance.
15 Jan
Cumberland Pharmaceuticals Inc. (CPIX) is navigating a healthcare landscape shaped by niche focus and regulatory challenges. The company is strategically positioning itself to leverage opportunities in specialized markets while addressing compliance and regulatory hurdles. This approach aims to enhance its product offerings and market presence, ultimately influencing its growth trajectory in the competitive pharmaceutical sector. Strategic positioning in niche markets and regulatory navigation are likely to significantly impact future performance and investor sentiment.